CRSP241018C46000
- 3.12
- +0.44+16.42%
CRISPR Therapeutics Newsroom
Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Truist Financial Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics Analyst Ratings
RBC Cuts Price Target on CRISPR Therapeutics to $53 From $60, Keeps Sector Perform Rating
CRISPR Therapeutics Analyst Ratings
Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating
Crispr Therapeutics AG: Strategic Progress and Strong Financials Bolstering a Buy Rating
Crispr Therapeutics AG Poised for Growth: Foroohar Maintains Buy Rating Amid Pipeline Progress and Strong Financials
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $105
Crispr Therapeutics AG (CRSP) Receives a Buy From Piper Sandler
Crispr Therapeutics Price Target Cut to $94.00/Share From $112.00 by Chardan Capital
Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $94
CRISPR Therapeutics Analyst Ratings
Barclays Sticks to Its Hold Rating for Crispr Therapeutics AG (CRSP)
Chardan Research Adjusts Price Target on CRISPR Therapeutics to $94 From $112, Maintains Buy Rating
Buy Rating Affirmed for Crispr Therapeutics AG Amid Strong Commercial Prospects and Robust Pipeline Growth
Rodman & Renshaw Initiates CRISPR Therapeutics at Buy With $90 Price Target
TD Cowen Reaffirms Their Sell Rating on Crispr Therapeutics AG (CRSP)
TD Cowen Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $30
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $88 Price Target